Cargando…
HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma
A suitable HPLC method has been selected and validated for rapid simultaneous separation and determination of four imidazole anti-infective drugs, secnidazole, omeprazole, albendazole, and fenbendazole, in their final dosage forms, in addition to human plasma within 5 min. The method suitability was...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794769/ https://www.ncbi.nlm.nih.gov/pubmed/33396585 http://dx.doi.org/10.3390/molecules26010129 |
_version_ | 1783634286941831168 |
---|---|
author | Ali, Oday T. Hassan, Wafaa S. Khayyat, Ahdab N. Almalki, Ahmad J. Sebaiy, Mahmoud M. |
author_facet | Ali, Oday T. Hassan, Wafaa S. Khayyat, Ahdab N. Almalki, Ahmad J. Sebaiy, Mahmoud M. |
author_sort | Ali, Oday T. |
collection | PubMed |
description | A suitable HPLC method has been selected and validated for rapid simultaneous separation and determination of four imidazole anti-infective drugs, secnidazole, omeprazole, albendazole, and fenbendazole, in their final dosage forms, in addition to human plasma within 5 min. The method suitability was derived from the superiority of using the environmentally benign solvent, methanol over acetonitrile as a mobile phase component in respect of safety issues and migration times. Separation of the four anti-infective drugs was performed on a Thermo Scientific(®) BDS Hypersil C(8) column (5 µm, 2.50 × 4.60 mm) using a mobile phase consist of MeOH: 0.025 M KH(2)PO(4) (70:30, v/v) adjusted to pH 3.20 with ortho-phosphoric acid at room temperature. The flow rate was 1.00 mL/min and maximum absorption was measured with UV detector set at 300 nm. Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity. The method of analysis was validated according to Food and Drug Administration (FDA)guidelines for the determination of the drugs, either in their dosage forms with highly precise recoveries, or clinically in human plasma, especially regarding pharmacokinetic and bioequivalence studies. |
format | Online Article Text |
id | pubmed-7794769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77947692021-01-10 HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma Ali, Oday T. Hassan, Wafaa S. Khayyat, Ahdab N. Almalki, Ahmad J. Sebaiy, Mahmoud M. Molecules Article A suitable HPLC method has been selected and validated for rapid simultaneous separation and determination of four imidazole anti-infective drugs, secnidazole, omeprazole, albendazole, and fenbendazole, in their final dosage forms, in addition to human plasma within 5 min. The method suitability was derived from the superiority of using the environmentally benign solvent, methanol over acetonitrile as a mobile phase component in respect of safety issues and migration times. Separation of the four anti-infective drugs was performed on a Thermo Scientific(®) BDS Hypersil C(8) column (5 µm, 2.50 × 4.60 mm) using a mobile phase consist of MeOH: 0.025 M KH(2)PO(4) (70:30, v/v) adjusted to pH 3.20 with ortho-phosphoric acid at room temperature. The flow rate was 1.00 mL/min and maximum absorption was measured with UV detector set at 300 nm. Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity. The method of analysis was validated according to Food and Drug Administration (FDA)guidelines for the determination of the drugs, either in their dosage forms with highly precise recoveries, or clinically in human plasma, especially regarding pharmacokinetic and bioequivalence studies. MDPI 2020-12-30 /pmc/articles/PMC7794769/ /pubmed/33396585 http://dx.doi.org/10.3390/molecules26010129 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ali, Oday T. Hassan, Wafaa S. Khayyat, Ahdab N. Almalki, Ahmad J. Sebaiy, Mahmoud M. HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma |
title | HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma |
title_full | HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma |
title_fullStr | HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma |
title_full_unstemmed | HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma |
title_short | HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma |
title_sort | hplc determination of imidazoles with variant anti-infective activity in their dosage forms and human plasma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794769/ https://www.ncbi.nlm.nih.gov/pubmed/33396585 http://dx.doi.org/10.3390/molecules26010129 |
work_keys_str_mv | AT aliodayt hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma AT hassanwafaas hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma AT khayyatahdabn hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma AT almalkiahmadj hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma AT sebaiymahmoudm hplcdeterminationofimidazoleswithvariantantiinfectiveactivityintheirdosageformsandhumanplasma |